
Jared Barsky
Examiner (ID: 7259, Phone: (571)272-2795 , Office: P/1628 )
| Most Active Art Unit | 1628 |
| Art Unit(s) | 1628 |
| Total Applications | 1117 |
| Issued Applications | 492 |
| Pending Applications | 146 |
| Abandoned Applications | 503 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18656075
[patent_doc_number] => 20230301946
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => THROMBOXANE RECEPTOR ANTAGONIST FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/014438
[patent_app_country] => US
[patent_app_date] => 2021-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13073
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014438
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/014438 | THROMBOXANE RECEPTOR ANTAGONIST FORMULATIONS | Jul 5, 2021 | Pending |
Array
(
[id] => 17168773
[patent_doc_number] => 20210322443
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => NON-BIOCONVERTIBLE C3-SUBSTITUTED PREGNENOLONE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/362669
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7249
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362669
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/362669 | NON-BIOCONVERTIBLE C3-SUBSTITUTED PREGNENOLONE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDERS | Jun 28, 2021 | Abandoned |
Array
(
[id] => 18483537
[patent_doc_number] => 20230210835
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY
[patent_app_type] => utility
[patent_app_number] => 18/011495
[patent_app_country] => US
[patent_app_date] => 2021-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21548
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011495
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/011495 | COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY | Jun 20, 2021 | Abandoned |
Array
(
[id] => 17292357
[patent_doc_number] => 20210388196
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => GENE DELIVERY CARRIER
[patent_app_type] => utility
[patent_app_number] => 17/347791
[patent_app_country] => US
[patent_app_date] => 2021-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36653
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17347791
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/347791 | GENE DELIVERY CARRIER | Jun 14, 2021 | Abandoned |
Array
(
[id] => 17214410
[patent_doc_number] => 20210347747
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/344680
[patent_app_country] => US
[patent_app_date] => 2021-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14953
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17344680
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/344680 | (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof | Jun 9, 2021 | Issued |
Array
(
[id] => 18953466
[patent_doc_number] => 20240041793
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => CURCUMINOID COMPOSITIONS WITH HIGH BIOAVAILABILITY
[patent_app_type] => utility
[patent_app_number] => 18/014549
[patent_app_country] => US
[patent_app_date] => 2021-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7050
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014549
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/014549 | CURCUMINOID COMPOSITIONS WITH HIGH BIOAVAILABILITY | Jun 7, 2021 | Pending |
Array
(
[id] => 18483493
[patent_doc_number] => 20230210790
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES
[patent_app_type] => utility
[patent_app_number] => 18/000471
[patent_app_country] => US
[patent_app_date] => 2021-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16160
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -71
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000471
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/000471 | GEL FOR USE IN GASTROINTESTINAL ENDOSCOPY AND ENDODERMAL, EPIDERMAL, AND OTHER MUCOSAL USES | Jun 1, 2021 | Pending |
Array
(
[id] => 18769276
[patent_doc_number] => 20230364032
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => USE OF 2-HOBA TO TREAT ATHEROSCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 17/928765
[patent_app_country] => US
[patent_app_date] => 2021-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18471
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928765
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/928765 | USE OF 2-HOBA TO TREAT ATHEROSCLEROSIS | May 31, 2021 | Pending |
Array
(
[id] => 18483492
[patent_doc_number] => 20230210789
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => METHODS FOR TREATING MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/000497
[patent_app_country] => US
[patent_app_date] => 2021-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12999
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000497
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/000497 | METHODS FOR TREATING MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION | May 27, 2021 | Pending |
Array
(
[id] => 18434216
[patent_doc_number] => 20230181510
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => COMPOSITION AND METHODS OF RETINOIC ACID
[patent_app_type] => utility
[patent_app_number] => 17/926388
[patent_app_country] => US
[patent_app_date] => 2021-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8348
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926388
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926388 | COMPOSITION AND METHODS OF RETINOIC ACID | May 20, 2021 | Abandoned |
Array
(
[id] => 18829536
[patent_doc_number] => 20230398060
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-14
[patent_title] => TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN
[patent_app_type] => utility
[patent_app_number] => 18/033104
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6118
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033104
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/033104 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | May 18, 2021 | Abandoned |
Array
(
[id] => 19360804
[patent_doc_number] => 20240262838
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/682421
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15032
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 307
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18682421
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/682421 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | May 18, 2021 | Pending |
Array
(
[id] => 17095342
[patent_doc_number] => 20210283133
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/321864
[patent_app_country] => US
[patent_app_date] => 2021-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51330
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17321864
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/321864 | Kinase inhibitor salts and compositions thereof | May 16, 2021 | Issued |
Array
(
[id] => 17050760
[patent_doc_number] => 20210260194
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
[patent_app_type] => utility
[patent_app_number] => 17/319898
[patent_app_country] => US
[patent_app_date] => 2021-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23924
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17319898
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/319898 | Pharmaceutical compositions comprising meloxicam | May 12, 2021 | Issued |
Array
(
[id] => 17050759
[patent_doc_number] => 20210260193
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
[patent_app_type] => utility
[patent_app_number] => 17/318691
[patent_app_country] => US
[patent_app_date] => 2021-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23889
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318691
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/318691 | Pharmaceutical compositions comprising meloxicam | May 11, 2021 | Issued |
Array
(
[id] => 17065746
[patent_doc_number] => 20210267961
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => METHOD OF TREATING LAMINOPATHIES
[patent_app_type] => utility
[patent_app_number] => 17/317170
[patent_app_country] => US
[patent_app_date] => 2021-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7818
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317170
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/317170 | METHOD OF TREATING LAMINOPATHIES | May 10, 2021 | Abandoned |
Array
(
[id] => 18793880
[patent_doc_number] => 11827632
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-28
[patent_title] => NLRP3 modulators
[patent_app_type] => utility
[patent_app_number] => 17/313319
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35297
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313319
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/313319 | NLRP3 modulators | May 5, 2021 | Issued |
Array
(
[id] => 17034994
[patent_doc_number] => 20210251952
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/308910
[patent_app_country] => US
[patent_app_date] => 2021-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13052
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308910
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/308910 | Compositions and methods for treating epilepsy, seizures and other conditions | May 4, 2021 | Issued |
Array
(
[id] => 17052074
[patent_doc_number] => 20210261508
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => METHODS FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS
[patent_app_type] => utility
[patent_app_number] => 17/229593
[patent_app_country] => US
[patent_app_date] => 2021-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13172
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17229593
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/229593 | METHODS FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS | Apr 12, 2021 | Abandoned |
Array
(
[id] => 17140140
[patent_doc_number] => 20210308151
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => ACTIVATING ENDOGENOUS ANTIMICROBIALS TO TREAT SARS-COV-2 INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/223631
[patent_app_country] => US
[patent_app_date] => 2021-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38200
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17223631
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/223631 | ACTIVATING ENDOGENOUS ANTIMICROBIALS TO TREAT SARS-COV-2 INFECTION | Apr 5, 2021 | Abandoned |